Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy

Sponsor
Seoul St. Mary's Hospital
Study ID
NCT01422018
Status
Unknown

Conditions

  • Diabetes Complications

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Avastin (bevacizumab) — DRUG
    Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)

Study Details

Purpose: To evaluate the efficacy of intravitreal bevacizumab (IVB) on focal edema with hard exudates secondary to diabetic retinopathy. Design: Prospective interventional case series. Participants: Ten eyes of 10 consecutive patients showing focal edema with hard exudates secondary to diabetic retinopathy which are not eligible for focal laser photocoagulation due to central location (\< 500 µm from fovea).

Key Dates

First listed
Aug 23, 2011
Start date
Aug 31, 2011
Status verified
Sep 2011
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: one arm for Anastin injection
    intravitreal Avastin injection

Primary Outcome Measure

Changes in best-corrected visual acuity (BCVA) [ Time Frame: from month 0 to month 6 in monthly schedule (upto 6 months) ]

Central Contacts

Related Studies